All patients are advised to discuss survival information with their hematologist-oncologists. Keep in mind that outcome data can only show how other people with CMML responded to treatment, and cannot predict how any one person will respond.
Unfortunately, lasting remissions are not common. The expected survival time ranges from a few months to a few years after the initiation of treatment, depending on a variety of risk factors including the percentage of blasts in the blood and marrow, the white blood cell count, and the presence of certain gene mutations.
CMML progresses to acute myeloid leukemia (AML) in approximately 15 to 30 percent of patients over 3-5 years. Those with the proliferative form of the disease (MP-CMML) tend to have a higher risk of transformation to AML.
- Download or order The Leukemia & Lymphoma Society's free booklet, Chronic Myelomonocytic Leukemia (CMML) and Juvenile Myelomonocytic Leukemia (JMML)